SIREN : 419570940
ARTHESYS is a French company founded 27 years ago, specialized in the sector Fabrication de matériel médico-chirurgical et dentaire. Based in SACLAY (91400), this company of category ETI shows in 2024 a revenue of 16.6 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Data updated on 2026-05-09
Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy
| Indicator | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 16 624 385 € | 13 190 841 € | 11 111 297 € | 11 731 168 € | 7 396 194 € | 23 394 736 € | 17 042 978 € | 10 321 095 € | 16 755 115 € |
| Net income | 1 288 476 € | -1 330 407 € | -1 680 166 € | 1 120 993 € | -1 025 361 € | -4 100 416 € | -826 657 € | -2 943 667 € | 2 982 709 € |
| EBITDA | 797 678 € | -2 746 769 € | -3 012 544 € | 4 433 081 € | -3 516 050 € | 865 459 € | -1 392 428 € | -4 764 194 € | 435 005 € |
| Net margin | 7.8% | -10.1% | -15.1% | 9.6% | -13.9% | -17.5% | -4.9% | -28.5% | 17.8% |
In 2024, ARTHESYS achieves revenue of 16.6 M€. Activity remains stable over the period (CAGR: -0.1%). Vs 2023, growth of +26% (13.2 M€ -> 16.6 M€). After deducting consumption (7.1 M€), gross margin stands at 9.5 M€, i.e. a rate of 57%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches 798 k€, representing 4.8% of revenue. Positive scissor effect: EBITDA margin improves by +25.6 pts, sign of improved operational efficiency. The operating margin remains fragile, requiring cost vigilance. Ultimately, net income (= EBIT +/- financial result +/- exceptional - corporate tax) amounts to 1.3 M€, i.e. 7.8% of revenue. This profit can be retained or distributed to shareholders.
16 624 385 €
9 545 069 €
797 678 €
2 108 064 €
1 288 476 €
4.8%
The debt ratio (= Financial debt / Equity x 100) stands at 112%. Debt level is high: negotiating margin with banks is reduced. Financial autonomy (= Equity / Total assets x 100) reaches 22%. The balance between equity and debt is satisfactory.
112.191%
22.194%
-1.679%
-14.676
24.1%
In 2024, the debt ratio of ARTHESYS (112.19) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.
In 2024, the financial autonomy of ARTHESYS (22.2%) ranks below the median of the sector. This ratio represents the share of equity in total financing. An improvement would strengthen the competitive position.
In 2024, the repayment capacity of ARTHESYS (-14.68) ranks in the bottom 25% of the sector, which is positive. This ratio indicates the number of years needed to repay debt with cash flow. A short capacity reflects controlled debt and good cash generation.
The liquidity ratio (= Current assets / Current liabilities) stands at 149.00. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months. The interest coverage ratio (= EBIT / Interest expenses) is 164.4x. Operating income very largely covers interest expenses: high safety margin.
149.002
164.444
In 2024, the liquidity ratio of ARTHESYS (149.00) ranks in the bottom 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio below 1 may signal potential cash flow tensions.
In 2024, the interest coverage of ARTHESYS (164.4x) ranks in the top 25% of the sector. This ratio indicates how many times operating income covers interest expenses. High coverage means financial charges weigh little on profitability.
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 149 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 249 days. Excellent situation: suppliers finance 100 days of the operating cycle (retail model). Inventory turnover is 73 days (= Average inventory / Cost of goods x 360). Overall, WCR represents 237 days of revenue, i.e. 10.9 M€ to permanently finance.
10 931 198 €
149 j
249 j
73 j
237 j
Based on 57 transactions of similar company sales
(all years),
the value of ARTHESYS is estimated at
2 928 778 €
(range 907 133€ - 5 787 375€).
With an EBITDA of 797 678€, the sector multiple of 2.5x is applied.
The price/revenue ratio is 0.23x
(conservative valuation).
This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Medium reliability: estimate to be confirmed with in-depth analysis.
Ajustez les pondérations selon votre analyse
This estimate is based on the analysis of 57 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Compare ARTHESYS with other companies in the same sector:
Voir toutes les statistiques du secteur Fabrication de matériel médico-chirurgical et dentaire
The revenue of ARTHESYS in 2024 is 16.6 M€.
Yes, ARTHESYS generated a net profit of 1.3 M€ in 2024.
The headquarters of ARTHESYS is located in SACLAY (91400), in the department Essonne.
The tax return of ARTHESYS is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
ARTHESYS operates in the sector Fabrication de matériel médico-chirurgical et dentaire (NAF code 32.50A). See the 'Sector positioning' section above to compare the company with its competitors.